aDepartment of Medicine, Division of Endocrinology, Metabolism and Nutrition bDepartment of Medicine, Division of Nephrology, Duke University Medical Center, Durham, North Carolina, USA.
Curr Opin Clin Nutr Metab Care. 2014 Jan;17(1):86-9. doi: 10.1097/MCO.0000000000000010.
There is burgeoning evidence that branch chain amino acids (BCAAs) are biomarkers of metabolic, cardiovascular, renal and cerebrovascular disease. The purpose of this review is to summarize the current evidence in this area.
Recent evidence demonstrates that BCAAs are associated with insulin resistance, type 2 diabetes, risk of cardiovascular disease, stage I and II chronic kidney disease and ischemic stroke. Further, circulating levels of BCAAs have the potential to predict populations at risk for cardiometabolic disease, type 2 diabetes and mortality from ischemic heart disease. Importantly, the relationship of BCAAs to insulin resistance is affected by the intake of fat in the diet as well as age.
Current evidence supports the potential use of BCAAs as biomarkers of disease. However, questions regarding the mechanisms underlying the relationship of BCAAs to disease process and severity need to be answered prior to the use of BCAAs as a biomarker in clinical practice.
越来越多的证据表明支链氨基酸（BCAAs）是代谢性、心血管、肾脏和脑血管疾病的生物标志物。本文的目的是总结这一领域的现有证据。
最近的证据表明，BCAAs 与胰岛素抵抗、2 型糖尿病、心血管疾病风险、I 期和 II 期慢性肾脏病以及缺血性中风有关。此外，循环 BCAAs 水平有潜力预测患心血管代谢疾病、2 型糖尿病和缺血性心脏病死亡率的人群。重要的是，BCAAs 与胰岛素抵抗的关系受到饮食中脂肪摄入以及年龄的影响。
现有证据支持将 BCAAs 作为疾病生物标志物的潜在用途。然而，在将 BCAAs 作为临床实践中的生物标志物之前，需要回答有关 BCAAs 与疾病过程和严重程度关系的潜在机制的问题。
